Simultaneous application of bevacizumab and anti-CTGF antibody effectively suppresses proangiogenic and profibrotic factors in human RPE cells

por Bagheri, Abouzar, Soheili, Zahra-Soheila, Ahmadieh, Hamid, Samiei, Shahram, Sheibani, Nader, Astaneh, Shamila Darvishalipour, Kanavi, Mozhgan Rezaei, Mohammadian, Azam
Publicado 2015